Cover Image
市場調查報告書

痛覺過敏症:開發平台分析

Hyperalgesia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 293882
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
痛覺過敏症:開發平台分析 Hyperalgesia - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 28 Pages
簡介

痛覺過敏症是對疼痛的反應增大。致病因子包含了長期使用Opioids(類鴉片物質)、發炎、侵害受體的損傷、末梢神經的損傷及精神的疾病等。治療方法有使用抗憂鬱症藥及非類固醇系抗發炎藥。

本報告提供痛覺過敏症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,及藥物簡介等相關的系統性資訊。

目錄

簡介

痛覺過敏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中的治療藥:大學/研究機關別

開發中產品概要

  • 初期階段的產品

開發中的產品:各企業

開發中的產品:大學/研究機關別

開發治療藥的企業

  • Cara Therapeutics, Inc.
  • 鹽野義製藥

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AX-007
  • BAM-822
  • CR-701
  • GERPOOI
  • ketoprofen
  • LASSBio-873
  • Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS
  • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia

最新開發平台趨勢

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8957IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia - Pipeline Review, H1 2017, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape.

Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and Non-steroidal anti-inflammatory drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperalgesia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperalgesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperalgesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperalgesia - Overview
  • Hyperalgesia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hyperalgesia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hyperalgesia - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim GmbH
    • Cara Therapeutics Inc
  • Hyperalgesia - Drug Profiles
    • AX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAM-822 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-113823 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GERP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LASSBio-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperalgesia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperalgesia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hyperalgesia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Hyperalgesia - Pipeline by Cara Therapeutics Inc, H1 2017
  • Hyperalgesia - Dormant Projects, H1 2017

List of Figures

  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
Back to Top